scholarly journals A Long-Acting Thermoresponsive Injectable Formulation of Tin Protoporphyrin Sustains Antitubercular Efficacy in a Murine Infection Model

2020 ◽  
Author(s):  
Oluwatoyin A. Adeleke ◽  
Logan Fisher ◽  
Ian N. Moore ◽  
Glenn A. Nardone ◽  
Alan Sher
Keyword(s):  
Infection Model ◽  
Injectable Formulation ◽  
Tin Protoporphyrin ◽  
Long Acting

Persistent efficacy of a long acting injectable formulation of moxidectin against natural infestations of the sheep nasal bot (Oestrus ovis) in Spain

2012 ◽  
Vol 188 (3-4) ◽  
pp. 330-336 ◽  
Author(s):  
Douglas Rugg ◽  
Luis Miguel Ferrer ◽  
Patxi Sarasola ◽  
Luis Figueras ◽  
Delia Lacasta ◽  
...  
Keyword(s):  
Oestrus Ovis ◽  
Injectable Formulation ◽  
Long Acting

Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation

2018 ◽  
Vol 38 (4) ◽  
pp. 365-369 ◽  
Author(s):  
Sara Baldelli ◽  
Massimo C. Mauri ◽  
Chiara Di Pace ◽  
Silvia Paletta ◽  
Alessandra Reggiori ◽  
...  
Keyword(s):  
Interindividual Variability ◽  
Injectable Formulation ◽  
Trough Concentrations ◽  
Long Acting

Development of a long-acting intramuscularly injectable formulation with nanosuspension of andrographolide

2016 ◽  
Vol 35 ◽  
pp. 327-332 ◽  
Author(s):  
Liandong Hu ◽  
Chenchen Yang ◽  
Dongqian Kong ◽  
Qiaofeng Hu ◽  
Na Gao ◽  
...  
Keyword(s):  
Injectable Formulation ◽  
Long Acting

scholarly journals Efficacy of moxidectin long-acting injectable formulation (1mg/kg bodyweight) against first instar larvae of Oestrus ovis in naturally infected sheep

2013 ◽  
Vol 193 (1-3) ◽  
pp. 320-324 ◽  
Author(s):  
M. Martínez-Valladares ◽  
F. Valcárcel ◽  
M.A. Álvarez-Sánchez ◽  
C. Cordero-Pérez ◽  
N. Fernández-Pato ◽  
...  
Keyword(s):  
Infected Sheep ◽  
Oestrus Ovis ◽  
Injectable Formulation ◽  
First Instar ◽  
Long Acting

scholarly journals Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay

2019 ◽  
Vol 63 (7) ◽  
Author(s):  
Paul J. Converse ◽  
Deepak V. Almeida ◽  
Sandeep Tyagi ◽  
Jian Xu ◽  
Eric L. Nuermberger
Keyword(s):  
Buruli Ulcer ◽  
Oxidase Inhibitor ◽  
Mycobacterium Ulcerans ◽  
Infection Model ◽  
Synergistic Activity ◽  
Content Type ◽  
Drug Regimens ◽  
Long Acting ◽  
Synthase Inhibitor

ABSTRACT Buruli ulcer is treatable with antibiotics. An 8-week course of rifampin (RIF) and either streptomycin (STR) or clarithromycin (CLR) cures over 90% of patients. However, STR requires injections and may be toxic, and CLR shares an adverse drug-drug interaction with RIF and may be poorly tolerated. Studies in a mouse footpad infection model showed that increasing the dose of RIF or using the long-acting rifamycin rifapentine (RPT), in combination with clofazimine (CFZ), a relatively well-tolerated antibiotic, can shorten treatment to 4 weeks. CFZ is reduced by a component of the electron transport chain (ETC) to produce reactive oxygen species toxic to bacteria. Synergistic activity of CFZ with other ETC-targeting drugs, the ATP synthase inhibitor bedaquiline (BDQ) and the bc1:aa3 oxidase inhibitor Q203 (now named telacebec), was recently described against Mycobacterium tuberculosis. Recognizing that M. tuberculosis mutants lacking the alternative bd oxidase are hypersusceptible to Q203 and that Mycobacterium ulcerans is a natural bd oxidase-deficient mutant, we tested the in vitro susceptibility of M. ulcerans to Q203 and evaluated the treatment-shortening potential of novel 3- and 4-drug regimens combining RPT, CFZ, Q203, and/or BDQ in a mouse footpad model. The MIC of Q203 was extremely low (0.000075 to 0.00015 μg/ml). Footpad swelling decreased more rapidly in mice treated with Q203-containing regimens than in mice treated with RIF and STR (RIF+STR) and RPT and CFZ (RPT+CFZ). Nearly all footpads were culture negative after only 2 weeks of treatment with regimens containing RPT, CFZ, and Q203. No relapse was detected after only 2 weeks of treatment in mice treated with any of the Q203-containing regimens. In contrast, 15% of mice receiving RIF+STR for 4 weeks relapsed. We conclude that it may be possible to cure patients with Buruli ulcer in 14 days or less using Q203-containing regimens rather than currently recommended 56-day regimens.

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

2009 ◽  
Vol 72 (3) ◽  
pp. 502-508 ◽  
Author(s):  
Lieven Baert ◽  
Gerben van ‘t Klooster ◽  
Willy Dries ◽  
Marc François ◽  
Alfons Wouters ◽  
...  
Keyword(s):  
Hiv Treatment ◽  
Injectable Formulation ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document